Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world multicenter study of intravenous levosimendan in acute heart failure
ChiCTR2400082198Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of levosimendan in Acute Heart Failure (AHF) and heart failure (HF), sponsored by Affiliated Hospital of Shandong University of Traditional Chinese Medicine. Primary endpoints: Change in NT-proBNP or BNP levels from pre- to post-treatment and Time to relief of wheezing/dyspnea symptoms. Started Mar 2024; status: recruiting.
02
Drugs
levosimendan
03
Conditions
Acute Heart Failure (AHF)heart failure (HF)
Beyond the preview
Go deeper on ChiCTR2400082198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082198.